◆英語タイトル:Neovacs SA (ALNEV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7554
◆発行会社(調査会社):
GlobalData
◆発行日:2018年10月
◆ページ数:42
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Neovacs SA (Neovacs) is a biotechnology company that develops various therapeutic vaccines for the treatment of autoimmune disorders, inflammatory diseases and cancers. The company offers TNF- kinoid and IFNalpha- kinoid products used for the treatment of rheumatoid arthritis, Crohn’s disease, systemic lupus erythematosus (SLE) or lupus. Its therapeutic vaccines use the patient’s own immune system to generate the production of natural antibodies neutralizing the overproduced cytokines responsible for the disease. Neovacs’ pipeline products portfolio includes VEGF-Kinoid for the treatment of age-related macular degeneration, solid tumors and IL4-Kinoid for the treatment of allergies. The company develops products using its proprietary kinoid technology that target cytokines for treatment of chronic autoimmune and inflammatory diseases. It conducts research and development activities on other high potential cytokine targets. Neovacs is headquartered in Paris, France.
Neovacs SA (ALNEV) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Neovacs SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Neovacs SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Neovacs SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Neovacs SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Neovacs SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Neovacs SA, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Neovacs to Acquire Interferon Alpha Manufacturing Technology from Amega Biotech 11
Partnerships 12
Neovacs Enters into Agreement with Sunnybrook Research Institute 12
Stellar Biotech and Neovacs Form Joint Venture 13
Licensing Agreements 14
Centurion Pharma Enters into Licensing Agreement with Neovacs 14
BioSense Exercises Option for Licensing Agreement with Neovacs 15
Chong Kun Dang Pharma Enters into Licensing Agreement with Neovacs 16
Equity Offering 17
Neovacs Raises USD1.2 Million in Private Placement of Shares 17
Neovacs Raises USD7 Million in Private Placement of Shares and Warrants 18
Neovacs Raises USD4.1 Million in Issue of Shares 20
Neovacs Raises USD9 Million in Rights Offering of Shares 21
Neovacs Raises USD8.4 Million in Private placement of Shares 22
Neovacs Raises Funds through Private Placement of Shares Upon Exercise of Warrants 23
Neovacs Raises Funds in Private Placement of Shares 24
Neovacs to Raise USD8.8 Million in Private Placement of Shares 25
Neovacs Announces Private Placement Of 1.97 Million Shares 26
Neovacs Completes Rights Offering Of Shares For US$11.4 Million 27
Debt Offering 28
Neovacs to Raise USD4.6 Million in Private Placement of Convertible Bonds Due 2020 28
Neovacs SA – Key Competitors 29
Neovacs SA – Key Employees 30
Neovacs SA – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Joint Venture 31
Recent Developments 32
Financial Announcements 32
Mar 30, 2018: Neovacs Provides Corporate Update and Reports Full-year 2017 Financial Results 32
Oct 27, 2017: Neovacs Provides Business Update and Announces Half-Year 2017 Financial Results 35
Mar 30, 2017: NEOVACS provides corporate update and reports full year 2016 financial results 37
Clinical Trials 39
Mar 09, 2017: Neovacs to present IFNalpha Kinoid technology and its clinical outlooks at upcoming Keystone Symposia Conference 39
Feb 03, 2017: Neovacs Announces Independent Data and Safety Monitoring Board Supports Continuation of Phase IIb Clinical Trial for IFNa Kinoid in Lupus 40
Jan 25, 2017: Neovacs Reports First Positive Immunogenicity Results for IFNa Kinoid in Model of Type 1 Diabetes 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42
List of Tables
Neovacs SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Neovacs SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Neovacs SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Neovacs SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Neovacs SA, Deals By Therapy Area, 2012 to YTD 2018 9
Neovacs SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Neovacs to Acquire Interferon Alpha Manufacturing Technology from Amega Biotech 11
Neovacs Enters into Agreement with Sunnybrook Research Institute 12
Stellar Biotech and Neovacs Form Joint Venture 13
Centurion Pharma Enters into Licensing Agreement with Neovacs 14
BioSense Exercises Option for Licensing Agreement with Neovacs 15
Chong Kun Dang Pharma Enters into Licensing Agreement with Neovacs 16
Neovacs Raises USD1.2 Million in Private Placement of Shares 17
Neovacs Raises USD7 Million in Private Placement of Shares and Warrants 18
Neovacs Raises USD4.1 Million in Issue of Shares 20
Neovacs Raises USD9 Million in Rights Offering of Shares 21
Neovacs Raises USD8.4 Million in Private placement of Shares 22
Neovacs Raises Funds through Private Placement of Shares Upon Exercise of Warrants 23
Neovacs Raises Funds in Private Placement of Shares 24
Neovacs to Raise USD8.8 Million in Private Placement of Shares 25
Neovacs Announces Private Placement Of 1.97 Million Shares 26
Neovacs Completes Rights Offering Of Shares For US$11.4 Million 27
Neovacs to Raise USD4.6 Million in Private Placement of Convertible Bonds Due 2020 28
Neovacs SA, Key Competitors 29
Neovacs SA, Key Employees 30
Neovacs SA, Subsidiaries 31
Neovacs SA, Joint Venture 31
List of Figures
Neovacs SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Neovacs SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Neovacs SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Neovacs SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Neovacs SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Neovacs SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Neovacs SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Neovacs SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9